

10/541394

JC14 Rec'd PCT/PTO 01 JUL 2005

PATENT
Customer No. 22,852
Attorney Docket No. 06267.0128

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
 Matti KIVIKKO et al.) Group Art Unit: Unassigned
)
 Application No.: Unassigned) Examiner: Unassigned
)
 Filed: Herewith)
)
 For: A METHOD FOR TREATING RENAL)
 FAILURE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed together with this application.

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and returning it to Applicants' undersigned representative.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do

JC14 Rec'd PCT/PTO 01 JUL 2005

not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 1, 2005

By: 

Steven J. Scott
Reg. No. 43,911

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	UNASSIGNED
		Filing Date	Filed Herewith
		First Named Inventor	Matti KIVIKKO
		Art Unit	UNASSIGNED
		Examiner Name	UNASSIGNED
Attorney Docket Number	06267.0128		
Sheet	1	of	1

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 92/12135	23 July 1992			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		XP00228338 & JP 04 368328 A (Teikoku Hormone Mfg Co Ltd) 21 December 1992 (1992-12-21) abstract, "Agent for treating chronic renal failure - contains 6-(4-acetyl-aminophenyl-4,5-di:hydro-5-methyl-3(2H)-pyridazinone."	
		Paul S. Pagel et al., "Pharmacology of Levosimendan: A New Myofilament Calcium Sensitizer," Cardiovascular Drug Reviews, Vol. 14, No. 3, pp. 286-316, 1996	
		Paul S. Pagel et al., "Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs," British Journal of Pharmacology, Vol. 119, pp. 609-615, 1996	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.